The CBD-ilemma
March 2022 The CBD-ilemma The approval of epidyolex for the treatment of refractory pediatric epilepsy is providing an increasing body of evidence on the therapeutic potential of cannabidiol (CBD), which had already showed promise to address other clinical conditions such as anxiety, psychotic symptoms, or substance use disorders. Owing to this therapeutical promise and fueled …